| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
45,766,000 |
| Market
Cap: |
808.69(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.29 - $46.14 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8 |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 16.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. Co.'s product portfolio are: ENROUTE Transcarotid Neuroprotection System, which is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, which is a self-expanding, self-tapering stent that conforms to patient; ENHANCE Transcarotid Peripheral Access Kit, which is used in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire, which is used for navigating and crossing the target lesion for delivery of interventional devices.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
11,700 |
11,700 |
11,700 |
11,700 |
| Total Buy Value |
$198,783 |
$198,783 |
$198,783 |
$198,783 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
27,257 |
27,913 |
50,523 |
602,067 |
| Total Sell Value |
$483,218 |
$487,552 |
$1,177,752 |
$28,445,866 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
6 |
7 |
15 |
58 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ballinger Kevin J. |
|
• • – |
2024-03-05 |
4 |
B |
$16.99 |
$198,783 |
D/D |
11,700 |
17,807 |
0.01 |
5% |
|
| Davis Andrew S. |
Chief Commercial Officer |
• • – |
2024-03-05 |
4 |
S |
$17.17 |
$94,103 |
D/D |
(5,481) |
287,773 |
|
-5% |
|
| Jones Marie L. |
VP, Finance and CAO |
• • – |
2024-03-05 |
4 |
S |
$17.17 |
$44,674 |
D/D |
(2,602) |
76,894 |
|
-5% |
|
| Klemz Kevin M |
EVP/Chief Legal Officer/Sec. |
• • – |
2024-03-05 |
4 |
S |
$17.17 |
$42,871 |
D/D |
(2,497) |
165,194 |
|
-5% |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• • – |
2024-03-05 |
4 |
S |
$17.17 |
$65,242 |
D/D |
(3,800) |
205,711 |
|
-5% |
|
| Buchanan Lucas W. |
COO/CFO |
• • – |
2024-03-05 |
4 |
S |
$17.17 |
$169,578 |
D/D |
(9,877) |
500,925 |
|
-5% |
|
| Davis Andrew S. |
Chief Commercial Officer |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
62,201 |
293,254 |
|
- |
|
| Jones Marie L. |
VP, Finance and CAO |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
24,555 |
79,496 |
|
- |
|
| Klemz Kevin M |
EVP/Chief Legal Officer/Sec. |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,818 |
167,691 |
|
- |
|
| Buchanan Lucas W. |
COO/CFO |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
74,954 |
510,802 |
|
- |
|
| Mckhann Chas |
Chief Executive Officer |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
110,313 |
722,396 |
|
- |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,674 |
209,511 |
|
- |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• • – |
2024-02-29 |
4 |
AS |
$22.25 |
$66,750 |
D/D |
(3,000) |
170,837 |
|
-4% |
|
| Jones Marie L. |
CAO and VP, Finance |
• • – |
2023-10-27 |
4 |
S |
$6.61 |
$4,334 |
D/D |
(656) |
54,941 |
|
-144% |
|
| Buchanan Lucas W. |
COO/CFO |
• • – |
2023-10-04 |
4 |
S |
$15.22 |
$40,524 |
D/D |
(2,662) |
435,848 |
|
-5% |
|
| Buchanan Lucas W. |
COO/CFO |
• • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
222,785 |
438,510 |
|
- |
|
| Klemz Kevin M |
EVP/Chief Legal Officer/Sec. |
• • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
86,076 |
124,873 |
|
- |
|
| Ruedy Richard |
EVPClin&Reg.Affairs&QA |
• • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
28,354 |
173,837 |
|
- |
|
| Davis Andrew S. |
Chief Commercial Officer |
• • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
121,519 |
231,053 |
|
- |
|
| Jones Marie L. |
CAO and VP, Finance |
• • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
7,595 |
55,597 |
|
- |
|
| Klemz Kevin M |
EVP/Chief Legal Officer/Sec. |
• • – |
2023-08-17 |
4 |
S |
$20.11 |
$30,942 |
D/D |
(1,539) |
38,797 |
|
41% |
|
| Davis Andrew S. |
Chief Commercial Officer |
• • – |
2023-08-03 |
4 |
S |
$22.13 |
$145,797 |
D/D |
(6,587) |
109,534 |
|
55% |
|
| Buchanan Lucas W. |
COO/CFO |
• • – |
2023-07-28 |
4 |
OE |
$1.60 |
$52,229 |
D/D |
9,643 |
215,725 |
|
- |
|
| Jones Marie L. |
CAO and VP, Finance |
• • – |
2023-07-20 |
4 |
OE |
$6.11 |
$12,220 |
D/D |
2,000 |
48,002 |
|
- |
|
| Rogers Erica J. |
President and CEO |
• • – |
2023-07-11 |
4 |
AS |
$31.56 |
$31,560 |
D/D |
(1,000) |
269,639 |
|
-75% |
|
410 Records found
|
|
Page 1 of 17 |
|
|
0.26 (1.49%) 
